Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03927456
- Locations
- 🇨🇳
Chinese Academy of Medical Science, Beijing, Beijing, China
A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
Phase 3
Completed
- Conditions
- Anesthesia for Elective Surgery Patients
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03921775
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
Phase 2
- Conditions
- EGFR-mutant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT03904823
- Locations
- 🇨🇳
Tongji University, Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03871855
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03870100
- Locations
- 🇨🇳
2nd Xiangya Hospital of Central South University, Changsha, China
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT03863860
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Pyrotinib, Trastuzumab, DocetaxelDrug: Placebo, Trastuzumab, Docetaxel
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 590
- Registration Number
- NCT03863223
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China
A Study of SHR-A1403 in Patients With Advanced Solid Tumor
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT03856541
- Locations
- 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, China
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT03848793
- Locations
- 🇨🇳
Nanjing Drum Tower hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase 2
- Conditions
- Endometrial CancerOvarian Cancer RecurrentRenal Cell CarcinomaUrothelial CarcinomaCervical Cancer
- Interventions
- Biological: SHR-1210
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 265
- Registration Number
- NCT03827837
- Locations
- 🇨🇳
Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath